550.96
Idexx Laboratories Inc stock is traded at $550.96, with a volume of 530.33K.
It is down -2.82% in the last 24 hours and up +1.90% over the past month.
Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx derives roughly 35% of its revenue from outside the United States.
See More
Previous Close:
$566.93
Open:
$569.14
24h Volume:
530.33K
Relative Volume:
0.81
Market Cap:
$43.41B
Revenue:
$4.45B
Net Income/Loss:
$1.10B
P/E Ratio:
40.54
EPS:
13.591
Net Cash Flow:
$1.06B
1W Performance:
-6.09%
1M Performance:
+1.90%
6M Performance:
-12.46%
1Y Performance:
-15.75%
Idexx Laboratories Inc Stock (IDXX) Company Profile
Name
Idexx Laboratories Inc
Sector
Industry
Phone
(207) 556-0300
Address
ONE IDEXX DRIVE, WESTBROOK, ME
Compare IDXX vs TMO, DHR, NTRA, A
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
|
IDXX
Idexx Laboratories Inc
|
550.96 | 44.95B | 4.45B | 1.10B | 1.06B | 13.59 |
|
TMO
Thermo Fisher Scientific Inc
|
588.29 | 222.96B | 45.20B | 6.87B | 6.75B | 18.19 |
|
DHR
Danaher Corp
|
202.45 | 144.67B | 24.78B | 3.68B | 5.29B | 5.1743 |
|
NTRA
Natera Inc
|
309.93 | 45.54B | 2.50B | -226.32M | 71.51M | -1.6412 |
|
A
Agilent Technologies Inc
|
148.53 | 41.87B | 7.23B | 1.41B | 1.09B | 4.979 |
Idexx Laboratories Inc Stock (IDXX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-15-26 | Initiated | Citigroup | Neutral |
| Dec-09-25 | Initiated | Barclays | Overweight |
| Oct-31-25 | Upgrade | Stifel | Hold → Buy |
| Oct-01-25 | Initiated | UBS | Neutral |
| Aug-05-25 | Reiterated | BTIG Research | Buy |
| Jul-01-25 | Initiated | Jefferies | Buy |
| Dec-02-24 | Initiated | Leerink Partners | Outperform |
| Jul-25-24 | Initiated | BTIG Research | Buy |
| Jan-30-24 | Downgrade | Piper Sandler | Overweight → Neutral |
| Dec-07-23 | Initiated | Exane BNP Paribas | Outperform |
| Dec-04-23 | Upgrade | Cleveland Research | Neutral → Buy |
| Aug-02-23 | Downgrade | Atlantic Equities | Overweight → Neutral |
| Jul-25-22 | Downgrade | Stifel | Buy → Hold |
| Jul-21-22 | Upgrade | Goldman | Neutral → Buy |
| Jul-12-22 | Initiated | Piper Sandler | Overweight |
| May-05-22 | Downgrade | BofA Securities | Buy → Neutral |
| Feb-08-22 | Initiated | Atlantic Equities | Overweight |
| Nov-18-21 | Initiated | Morgan Stanley | Overweight |
| Aug-05-21 | Resumed | Credit Suisse | Outperform |
| Jul-12-21 | Downgrade | Guggenheim | Buy → Neutral |
| Feb-17-21 | Initiated | Barclays | Overweight |
| Sep-09-19 | Initiated | Goldman | Neutral |
| May-23-19 | Initiated | Guggenheim | Buy |
| Nov-02-18 | Reiterated | BofA/Merrill | Buy |
| May-07-18 | Reiterated | Stifel | Buy |
| Jan-16-18 | Initiated | Piper Jaffray | Overweight |
| Aug-23-17 | Upgrade | BofA/Merrill | Neutral → Buy |
| Jul-28-17 | Upgrade | CL King | Neutral → Buy |
| Feb-03-17 | Downgrade | Feltl & Co. | Hold → Sell |
| Sep-29-16 | Resumed | BofA/Merrill | Neutral |
| Aug-16-16 | Reiterated | Stifel | Buy |
| Aug-03-16 | Upgrade | Northcoast | Sell → Neutral |
| Jul-20-16 | Reiterated | Canaccord Genuity | Buy |
| Apr-19-16 | Reiterated | Canaccord Genuity | Buy |
| Apr-01-16 | Initiated | CL King | Neutral |
| Mar-21-16 | Reiterated | Stifel | Buy |
| Feb-04-16 | Initiated | Credit Suisse | Outperform |
| Oct-29-15 | Reiterated | Stifel | Buy |
| Aug-28-15 | Downgrade | Raymond James | Outperform → Mkt Perform |
| Aug-13-15 | Reiterated | Stifel | Buy |
| Jul-23-15 | Reiterated | Canaccord Genuity | Buy |
View All
Idexx Laboratories Inc Stock (IDXX) Latest News
IDEXX Laboratories Targets $45B Pet Diagnostics Opportunity With AI, Cancer Tests - Yahoo Finance
Handelsbanken Fonder AB Grows Position in IDEXX Laboratories, Inc. $IDXX - MarketBeat
IDEXX Laboratories, Inc. (IDXX) Stock forecasts - Yahoo Finance Singapore
IDEXX Laboratories, Inc. (IDXX) Stock Forecasts - Yahoo Finance
IDEXX Laboratories Inc. stock underperforms Wednesday when compared to competitors - MarketWatch
IDXX|IDEXX Laboratories Inc|Price:569.852|Chg%:-0.728 - TradingKey
IDEXX Laboratories Inc. stock underperforms Tuesday when compared to competitors - MarketWatch
IDEXX Laboratories Launches Catalyst proBNP Test for In-Clinic Cardiac Disease Assessment - marketscreener.com
IDEXX launches in-clinic cardiac test for cats and dogs - Investing.com
IDEXX Expands Catalyst Platform into Cardiac Disease with First and Only Dual-Species Point-of-Care NT-proBNP Test - Eagle-Tribune
Barclays Adjusts Price Target on IDEXX Laboratories to $710 From $800, Keeps Overweight Rating - marketscreener.com
IDEXX Laboratories Inc. stock outperforms competitors on strong trading day - MarketWatch
NewEdge Advisors LLC Acquires 5,761 Shares of IDEXX Laboratories, Inc. $IDXX - MarketBeat
IDEXX Laboratories Inc (IDXX) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Seilern Investment Management Ltd Purchases 16,729 Shares of IDEXX Laboratories, Inc. $IDXX - MarketBeat
IDEXX Laboratories Inc Stock Historical Valuations | HAM:IX1 - GuruFocus
IDEXX Laboratories Inc Stock Baskets - GuruFocus
IDEXX Laboratories Inc (HAM:IX1) Stock Forecast, Price Targets and Analysts Predictions - GuruFocus
IDEXX Laboratories Inc (HAM:IX1) Stock Price & 30 Year Financial Data - GuruFocus
IDEXX Laboratories (HAM:IX1) Other Operating Expense : €0 Mil (TTM As of Jun. 2026) - GuruFocus
IDEXX Laboratories (HAM:IX1) Marketable Securities : €0 Mil (As of Jun. 2026) - GuruFocus
IDEXX Laboratories Inc (HAM:IX1) Competitors 2026 - GuruFocus
IDEXX Laboratories Inc (HAM:IX1) Stock News, Headlines & Updates - GuruFocus
Who's Buying or Selling IDEXX Laboratories Inc (HAM:IX1) Stock Today? - GuruFocus
IDEXX Laboratories Inc (IDXX) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
IDEXX Labs posts 9% organic growth, raises EPS forecast, driven by global diagnostic expansion. - Pluang
IDEXX Laboratories: Worth The Premium (NASDAQ:IDXX) - Seeking Alpha
IDEXX Laboratories, Inc. $IDXX Shares Sold by Beacon Investment Advisory Services Inc. - MarketBeat
Assenagon Asset Management S.A. Boosts Position in IDEXX Laboratories, Inc. $IDXX - MarketBeat
Aurora Investment Managers LLC. Makes New Investment in IDEXX Laboratories, Inc. $IDXX - MarketBeat
What Does IDEXX Laboratories, Inc.'s (NASDAQ:IDXX) Share Price Indicate? - Moomoo
Janus Henderson Group PLC Cuts Stock Holdings in IDEXX Laboratories, Inc. $IDXX - MarketBeat
Clinical Visits Keep Falling. IDEXX Laboratories’ Q2 Earnings Report Say That Doesn’t Matter. - TIKR.com
IDEXX Laboratories, Inc. $IDXX Shares Sold by Empowered Funds LLC - MarketBeat
IDEXX Laboratories (NASDAQ:IDXX) Stock Price Expected to Rise, UBS Group Analyst Says - MarketBeat
IDEXX Labs Is Maintained at Neutral by UBS - Moomoo
IDEXX Labs Is Maintained at Neutral by Citigroup - Moomoo
Jefferies Adjusts Price Target on IDEXX Laboratories to $795 From $792 - Moomoo
UBS Maintains IDEXX Laboratories Inc(IDXX.US) With Hold Rating, Raises Target Price to $670 - Moomoo
Citi Maintains IDEXX Laboratories Inc(IDXX.US) With Hold Rating, Raises Target Price to $670 - Moomoo
IDEXX Laboratories Inc (HAM:IX1) Stock Earnings Transcripts - GuruFocus
IDEXX (IDXX) Stock Rewards Margin Strength And Recurring Diagnostics Growth - Sahm
IDEXX Laboratories Inc (IDXX) Stock Up 3.6% and Still Undervalued -- GF Score: 96/100 - GuruFocus
IDEXX Laboratories, Inc. Q2 2026 Earnings Call Summary - Yahoo Finance
IDEXX Laboratories Inc (IDXX) (Q2 2026) Earnings Call Highlights: Strong Revenue Growth and ... - Yahoo Finance
IDEXX Laboratories Inc (IDXX) (Q2 2026) Earnings Call Highlights - GuruFocus
IDEXX Laboratories 2026: Revenue $1.22B, EPS $4.27— 10-Q Summary - TradingView
IDEXX Laboratories (NASDAQ: IDXX) lifts Q2 2026 profit and cash flow - Stock Titan
IDEXX Laboratories, Inc. Stock 12‑Month Price Target Raised to $719, Implies 27% Upside - TradingView
Idexx Laboratories, Inc. Updates Earnings Guidance for 2026 - marketscreener.com
IDEXX Laboratories jumps 5% on strong results, raised guidance (IDXX:NASDAQ) - Seeking Alpha
Idexx Laboratories Inc Stock (IDXX) Financials Data
Revenue
Net Income
Cash Flow
EPS
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):